3.80Open3.80Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.01%IV0.00%PremiumMay 17, 2024Expiry Date3.85Intrinsic Value100Multiplier-2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-1.0000Delta0.0000Gamma0.95Leverage Ratio0.0000Theta0.0000Rho-0.95Eff Leverage0.0000Vega
Acumen Pharmaceuticals Stock Discussion
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...
slowly moving up
No comment yet